Search
forResearch 10 of 1000+
- Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
- Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
- Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata
- Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Rat steroid 5α-reductase kinetic characteristics: Extreme pH-dependency of the type II isozyme in prostate and epididymis homogenates
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Phase separation: a new window in RALF signaling
- Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
- Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Community 10 of 421
- Phase 3 Study for PP405 officially posted
- Phase 3 for PP405 will now start in 2027
- So why did the first pyrilutamide phase III fail?
- A minoxidil pill just posted strong phase 3 results. Up to 86% of men improved coverage in six months.
- Phase 2B trial for PP405 leaked (The study Pelage DOESN'T want you to see)
- Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
- Pelage PP405: New Hair Growth from Inactive Follicular Units - Phase 2a results at AAD 2026
- TH07 by Triple Hair entering phase III trial
- Phase II topical dut study - outperforms oral fin with a minor DHT reduction
- Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Learn
— no results
Try a deeper search in learn →